A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats
COPD-Related Inflammation Could Achieve Blockbuster Status
Although Physicians Report Satisfaction with GlaxoSmithKline's Advair and
Boehringer Ingelheim/Pfizer's Spiriva, Significant Need Remains for a Novel
Anti-Inflammatory Drug, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 27 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that surveyed physicians indicate that a novel, non-
steroidal, anti-inflammatory agent for COPD that improves lung function could
capture a significant share of the COPD market by replacing GlaxoSmithKline's
Advair (also marketed as Seretide and Adoair).
The new report entitled Chronic Obstructive Pulmonary Disease: Opportunity
Lies in Drugs That Address COPD-Related Inflammation finds that an oral, once-
daily drug that treats COPD-related inflammation and improves lung function
could achieve blockbuster status by 2016. Although an effective anti-
inflammatory drug for COPD could replace Advair, it would likely be used in
combination with Boehringer Ingelheim/Pfizer's Spiriva, according to the
report. Spiriva's efficacy, safety, and convenience make it the current gold
standard treatment for COPD but Advair's higher price, longer presence on the
market and high prescribing by doctors made Advair the COPD market-share
leader in 2006.
The report also finds that, following its approval in 2011 for the
indication, Forest Laboratories/Almirall Prodesfarma's aclidinium will become
the clinical gold standard for COPD by 2016. Aclidinium, a long-acting
muscarinic antagonist (LAMA), will achieve gold standard status by 2016
because of its faster onset of action when compared to Spiriva.
"Because Spiriva is the first-to-market LAMA and has extensive clinical
data and physician experience, we don't expect aclidinium to immediately
achieve wide acceptance upon launch as the gold standard for COPD as
physicians must first gain clinical experience with the drug," said Regina
Jammen, analyst at Decision Resources. "We expect that clinical trials,
specifically the UPLIFT trial, will provide results showing the benefits of
the long-term use of Spiriva in COPD patients, and these results are likely to
be generalized to other agents in the LAMA drug class, such as aclidinium."
About the Report
Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That
Address COPD-Related Inflammation is a DecisionBase 2008 report from Decision
Resources. DecisionBase 2008 combines market forecasts with clinical and
commercial end points to assess market share projections in 35 indications.
These outputs are driven by quantitative and qualitative primary research.
DecisionBase 2008 provides detailed market share, patient share, and price-
per-day projections for emerging drugs in development. The market share
projections are based on prescriber surveys that compare physicians'
expectations of a potential target product profile with an emerging product
profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of
the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in
market research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources
Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com
